WATERTOWN, Mass.--(BUSINESS WIRE)--March 27, 2006--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC) which, when declared effective by the SEC, will allow Panacos from time to time to offer and sell up to $100 million of equity securities. The terms of any offering made pursuant to this filing will be established at the time of the offering. The Company intends to use the proceeds from the sale of any securities to fund its internal discovery and development programs including the clinical development of its HIV therapeutic drug candidate PA-457, and for other general corporate purposes.
